| Savella (milnacipran) / AbbVie, Pierre Fabre |
2004-004249-16: THE EFFECT OF MILNACIPRAN 100MG BID ON SENSITIVITY TO STIMULUS-EVOKED PAIN IN PATIENTS WITH FIBROMYALGIA: A FMRI NEUROIMAGING STUDY |
|
|
| Completed | 2 | 144 | Europe | N/A, F02207, Capsule, hard | PIERRE FABRE MEDICAMENT | Fibromyalgia is a chronic disorder characterized by widespread musculoskeletal pain, widespread tenderness and fatigue. The disorder is well defined in the USA, where the current diagnosis of FMS is based on the criteria set forth by the American College of Rheumatology (ACR) in 19901. | | | | |
NCT00757679: Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran |
|
|
| Completed | 2 | 153 | Europe | Milnacipran, Placebo | Pierre Fabre Medicament | Fibromyalgia Syndrome | 09/09 | 09/09 | | |
NCT01225068: Effect of Milnacipran in Chronic Neuropathic Low Back Pain |
|
|
| Completed | 2 | 40 | US | Milnacipran, Savella, Placebo | Northwestern University, Forest Laboratories, Shirley Ryan AbilityLab, Best Practice | Low Back Pain | 01/12 | 04/12 | | |
2012-002302-43: A study of the effect of buprenorphine in combination with milnacipran in a pain model in healthy volunteers. |
|
|
| Completed | 2 | 10 | Europe | Buprenorpine, milnacipran, 2217180, Solution for infusion, Capsule, Temgesic, Ixel | Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Ltd. | Pain therapeutics, neuropathic pain, nociceptive pain, synergism between opioids and TCA., Long term pain treatment, acute term pain treatment, combination treatment., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT01331109: Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia |
|
|
| Terminated | 2 | 57 | US | Milnacipran | Forest Laboratories, Cypress Bioscience, Inc. | Primary Fibromyalgia | 08/12 | 08/12 | | |
MyFi, NCT01328002: Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia |
|
|
| Terminated | 2 | 116 | US | Milnacipran, Savella, Placebo | Forest Laboratories, Cypress Bioscience, Inc. | Primary Fibromyalgia | 08/12 | 08/12 | | |
NCT01471379: Milnacipran (Savella) in Irritable Bowel Syndrome (IBS) |
|
|
| Terminated | 2 | 2 | US | Milnacipran, Savella, Placebo | Spencer Dorn, MD, MPH, Forest Laboratories | Irritable Bowel Syndrome | 02/13 | 02/13 | | |
NCT01747044: Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy |
|
|
| Unknown status | 2 | 48 | Europe | Milnacipran, Placebo | University Hospital, Clermont-Ferrand, Dr. Gisèle PICKERING (MCU, PH) Center of clinical pharmacology/CIC Inserm-501 - Main investigator, Dr Pascale PICARD/ Dr Noémie Delage / Dr Fabienne RIAUX - Center of evaluation and treatment of the pain - Investigator, Dr Gilles DUCHEIX/ Center of clinical pharmacology/CIC Inserm-501 - Investigator, Dr Christian DUALE/ Center of clinical pharmacology/CIC Inserm-501 - Investigator | Fibromylagia | 11/14 | 11/14 | | |
2012-003222-24: / Etude prospective de l’influence des faisceaux inhibiteurs descendants de la douleur sur l’efficacité du milnacipran utilisé pour la fibromyalgie. |
|
|
| Completed | 2 | 52 | Europe | Capsule, IXEL 50mg | CHU de Clermont-Ferrand, CHU de Clermont-Ferrand | / Douleur et fibromyalgie, / Douleur et Fibromyalgie, Body processes [G] - Metabolic Phenomena [G03] | | | | |
CP-PTLS, NCT05055622: Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome |
|
|
| Terminated | 2 | 10 | NA | Milnacipran with D-cycloserine augmentation, Milnacipran with placebo augmentation | Research Foundation for Mental Hygiene, Inc. | Post Treatment Lyme Syndrome, Chronic Pain, Central Sensitization | 01/18 | 01/18 | | |
NCT01914042: Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica |
|
|
| Unknown status | 2 | 150 | RoW | Morphine, Milnacipran | Rambam Health Care Campus | Neuropathic Pain | 07/19 | 12/19 | | |
